Odyssey Therapeutics: $101 Million Secured To Pioneer Next-Gen Precision Immunomodulators And Oncology Medicines
By Amit Chowdhry ● Dec 18, 2023
Odyssey Therapeutics - a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines - recently announced the closing of a $101 million Series C financing round led by Ascenta Capital with participation from new and existing investors, including OrbiMed, SR One, General Catalyst, Foresite Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures, BlackMars Capital GmbH, Creacion Ventures, funds and accounts advised by Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, Racing Beach Ventures LLC, The Healthcare Innovation Investment Fund LLC (an investment fund associated with Leerink Partners), Ab Magnitude Ventures, KB Investment, The Global BioAccess Fund, and multiple leading global investors.